Sanzyme Biotics

Sanzyme Biotics is a specialized biotechnology company and a global pioneer in the field of probiotics and fermentation technology. Originally established as part of the Indo-Japanese joint venture Uni-Sankyo in 1969, the company focuses on the development and large-scale manufacturing of science-backed probiotic strains, most notably the proprietary Bacillus coagulans SNZ 1969. In 2022, its leading portfolio of brands, including the popular Sporlac franchise, was acquired by JB Chemicals & Pharmaceuticals for approximately $84 million to lead the Indian probiotics market. Today, Sanzyme Biotics continues to operate as a specialized manufacturer and R&D hub, providing high-quality ingredients and CDMO services to the pharmaceutical, nutraceutical, and food industries across more than 40 countries.